Overview

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

Status:
Completed

Trial end date:
2018-10-01

Target enrollment:
0

Participant gender:
All

Summary

This study is looking at differences in metabolism and functional imaging between pulmonary hypertension subjects with normal right ventricular function and persistent right ventricular dysfunction.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Brigham and Women's Hospital
University of Pennsylvania

Collaborators:

Brigham and Women's Hospital
The Cardiovascular Medical Research and Education Fund
University of Maryland
University of Maryland, College Park
University of Pennsylvania
Washington University School of Medicine
Yale University

Treatments:

Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

Participation in the companion treatment protocol "A randomized, double-blind, placebo
controlled, multi-center study to assess the effect of ranolazine on outcomes in subjects
with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative
study of cellular metabolism in subjects with pulmonary hypertension with and without right
ventricular dysfunction"

Exclusion Criteria:

- Pregnancy or lactation: Women of childbearing potential must have a negative urine or
blood pregnancy test on the day of the PET/CT scan.

- Severe anxiety or claustrophobia prohibiting completion of imaging

- Inability to tolerate imaging procedures (1 hour MRI, 30 min and 15 min PET)

- Implantable cardioverter-defibrillator, Pacemaker, hazardous metallic implants or any
other contraindication to MRI.

- Uncontrolled diabetes mellitus with fasting glucose > 150 mg/dL